<?xml version="1.0" encoding="UTF-8"?>
<results title="test_trace">
 <result pre="of SFTS is high (6–30%), development of specific and effective" exact="treatment" post="for SFTS is required. Studies of potential antiviral drugs"/>
 <result pre="expected. Humans become infected mainly via tick-bites, but through close" exact="contact" post="with animals such as cats, and dogs and human-to-human"/>
 <result pre="available effective SFTS treatment. The development of vaccines against SFTSV" exact="infection" post="has been attempted (Dong et al., 2019; Kwak et"/>
 <result pre="al., 2019; Kwak et al., 2019). The development of specific" exact="treatment" post="for SFTS is crucial because SFTSV infection is relatively"/>
 <result pre="development of specific treatment for SFTS is crucial because SFTSV" exact="infection" post="is relatively rare and the affected patients are mainly"/>
 <result pre="been conducted to identify effective antiviral agents against SFTSV by" exact="screening" post="compound libraries or testing agents that are effective against"/>
 <result pre="effective antiviral agents against SFTSV by screening compound libraries or" exact="testing" post="agents that are effective against other viruses (Table 1)."/>
 <result pre="been suggested that antiviral drugs may potentially be effective in" exact="treatment" post="of multiple viral infections, testing approved drugs is considered"/>
 <result pre="may potentially be effective in treatment of multiple viral infections," exact="testing" post="approved drugs is considered as a reasonable strategy (De"/>
 <result pre="required to evaluate the efficacy of antiviral drugs in the" exact="treatment" post="of SFTSV infections. However, adult mice and hamsters are"/>
 <result pre="However, adult mice and hamsters are not susceptible to SFTSV" exact="infection" post="(Jin et al., 2012) and non-human primate models show"/>
 <result pre="et al., 2019) were found to be susceptible to SFTSV" exact="infection" post="following subcutaneous inoculation, and newborn mice and rats were"/>
 <result pre="inoculation, and newborn mice and rats were susceptible to SFTSV" exact="infection" post="when inoculated intracerebrally (Chen et al., 2012; Zivcec et"/>
 <result pre="article, we summarize and discuss recent advancements made in SFTSV" exact="treatment" post="using antiviral drugs. Potential Therapeutic Drugs Against SFTS Ribavirin"/>
 <result pre="osteosarcoma-derived U2OS cells. When treated with ribavirin before and during" exact="infection" post="with SFTSV, the 99% inhibitory concentration (IC99) of ribavirin"/>
 <result pre="2017) (Table 1). Despite several differences in viral strains and" exact="treatment" post="procedure, ribavirin suppressed SFTS replication, suggesting that it was"/>
 <result pre="reported that two patients, in whom plasma exchange and ribavirin" exact="treatment" post="were initiated early, recovered from rapidly progressing SFTS (Oh"/>
 <result pre="or 100 mg/kg/day lost body weight and died from SFTSV" exact="infection" post="with reduction of the case fatality rate. All favipiravir-treated"/>
 <result pre="the case fatality rate. All favipiravir-treated mice survived when the" exact="treatment" post="was initiated on or earlier than 3 days post"/>
 <result pre="whereas the mice treated at 4 and 5 days post" exact="infection" post="exhibited 83% and 50% survival, respectively (Tani et al.,"/>
 <result pre="administration in a mouse model (Tani et al., 2016). Furthermore," exact="treatment" post="with favipiravir (300 or 150 mg/kg/day) provided complete protection"/>
 <result pre="120 and 200 mg/kg/day p.o. was investigated in a mouse" exact="infection" post="model, and all the mice survived when the treatment"/>
 <result pre="mouse infection model, and all the mice survived when the" exact="treatment" post="was initiated at no later than 4 days post"/>
 <result pre="treatment was initiated at no later than 4 days post" exact="infection" post="(Tani et al., 2018). Hexachlorophene Yuan et al. (2019)"/>
 <result pre="antifungal disinfectants (hexachlorophene and triclosan), a multi-kinase inhibitor for the" exact="treatment" post="of advanced solid organ tumors (regorafenib), a small molecule"/>
 <result pre="agonist of the C-mannosylation of thrombopoietin receptor (c-Mpl) for the" exact="treatment" post="of immune thrombocytopenic purpura and aplastic anemia (eltrombopag), and"/>
 <result pre="drugs identified (Table 1). Furthermore, the results indicated that hexachlorophene" exact="treatment" post="interfered with SFTSV entry without affecting virus-host cell attachment"/>
 <result pre="and budding. The results of in vitro study suggested that" exact="treatment" post="with benidipine hydrochloride or nifedipine inhibited SFTSV replication by"/>
 <result pre="in C57BL/6 mice and humanized mouse models (Table 2), revealing" exact="treatment" post="effects of a reduced viral load, increased platelet count,"/>
 <result pre="an in vivo study using IFNAR−/− mice, a 100 mg/kg/day" exact="treatment" post="with 2′-FdC was 100% protective against death caused by"/>
 <result pre="was more effective than 2′-FdC in controlling morbidity during the" exact="infection" post="(Smee et al., 2018). It was also found that"/>
 <result pre="al. (2019) used enzyme-linked immunosorbent assays to demonstrate that SFTSV" exact="infection" post="caused a substantial production of serum IFN-γ in patients"/>
 <result pre="vivo in a suckling mouse model, which showed that IFN-γ" exact="treatment" post="prior to SFTSV infection significantly reduced mortality, protecting ~25%"/>
 <result pre="mouse model, which showed that IFN-γ treatment prior to SFTSV" exact="infection" post="significantly reduced mortality, protecting ~25% of animals from death,"/>
 <result pre="rate of patients with SFTS, discouraged us from considering ribavirin" exact="treatment" post="for treating patients with SFTS. However, Li et al."/>
 <result pre="Meanwhile, favipiravir remained effective when it was used following SFTSV" exact="infection" post="in animal models (Tani et al., 2016, 2018; Gowen"/>
 <result pre="was found to be effective for SFTSV in in vitro" exact="screening" post="using an FDA-approved drug library (Yuan et al., 2019)."/>
 <result pre="Still, these findings indicated the potential therapeutic effect of CCB" exact="treatment" post="in patients with SFTS. 2′-FdC is considered a viable"/>
 <result pre="other drugs (Shimojima et al., 2015). The efficacy of antibody-based" exact="treatment" post="has been studied against SFTS disease. Generally, antibodies play"/>
 <result pre="patient recovered from SFTS completely protected mice from the lethal" exact="infection" post="of SFTSV (Shimada et al., 2015). It was also"/>
 <result pre="the fatality rate in mice infected with SFTSV, even when" exact="treatment" post="was initiated from 3 days post inoculation (Kim et"/>
 <result pre="SFTS. There are two studies for developing vaccines against SFTSV" exact="infection" post="(Dong et al., 2019; Kwak et al., 2019). A"/>
 <result pre="stomatitis virus expressing SFTSV antigen completely protected mice from SFTSV" exact="infection" post="(Dong et al., 2019). A DNA vaccine expressing antigens"/>
 <result pre="T cell response and protected aged-ferrets from the lethal SFTSV" exact="infection" post="(Kwak et al., 2019). Safe and effective vaccines against"/>
 <result pre="T.et al.. (2017). Modeling severe fever with thrombocytopenia syndrome virus" exact="infection" post="in golden syrian hamsters: importance of STAT2 in preventing"/>
 <result pre="syrian hamsters: importance of STAT2 in preventing disease and effective" exact="treatment" post="with favipiravir. J. Virol.91, e01942–e01916. 10.1128/JVI.01942-1627881648 GraciJ. D.CameronC. E."/>
 <result pre="SARS-CoV. FEBS Lett.574, 116–120. 10.1016/j.febslet.2004.08.01515358550 JinC.JiangH.LiangM.HanY.GuW.ZhangF.et al.. (2015). SFTS virus" exact="infection" post="in nonhuman primates. J. Infect. Dis.211, 915–925. 10.1093/infdis/jiu56425326554 JinC.LiangM.NingJ.GuW.JiangH.WuW.et"/>
 <result pre="anti-Gn glycoprotein antibody from a convalescent patient potently inhibits the" exact="infection" post="of severe fever with thrombocytopenia syndrome virus. PLoS Pathog.15:e1007375."/>
 <result pre="a SFTSV DNA vaccine that confers complete protection against lethal" exact="infection" post="in ferrets. Nat. Commun. 10, 1–11. 10.1038/s41467-019-11815-430602773 LanglandJ.JacobsB.WagnerC. E.RuizG.CahillT."/>
 <result pre="(2014). The pathogenesis of severe fever with thrombocytopenia syndrome virus" exact="infection" post="in alpha/beta interferon knockout mice: insights into the pathologic"/>
 <result pre="and People's Republic of China (2011). Guideline for prevention and" exact="treatment" post="of severe fever with thrombocytopenia syndrome (2010 version). Chinese"/>
 <result pre="10.3201/eid1905.12024523648209 OgawaM.ShirasagoY.AndoS.ShimojimaM.SaijoM.FukasawaM. (2018). Caffeic acid, a coffee-related organic acid, inhibits" exact="infection" post="by severe fever with thrombocytopenia syndrome virus in vitro."/>
 <result pre="Virol.84, 8721–8731. 10.1128/JVI.00144-1020538858 ShimadaS.PosadasH. G.AokiK.MoritaK.HayasakaD. (2015). Therapeutic effect of post-exposure" exact="treatment" post="with antiserum on severe fever with thrombocytopenia syndrome (SFTS)"/>
 <result pre="caffeic acid p-nitro-phenethyl ester in vitro and in vivo and" exact="detection" post="of its metabolites. Sci. Rep.7:7599. 10.1038/s41598-017-07953-828790461 TaniH.FukumaA.FukushiS.TaniguchiS.YoshikawaT.Iwata-yoshikawaN.et al.. (2016)."/>
 <result pre="10.1038/s41598-017-07953-828790461 TaniH.FukumaA.FukushiS.TaniguchiS.YoshikawaT.Iwata-yoshikawaN.et al.. (2016). Efficacy of T-705 (Favipiravir) in the" exact="treatment" post="of infections with lethal severe fever with thrombocytopenia syndrome"/>
 <result pre="effects of favipiravir against severe fever with thrombocytopenia syndrome virus" exact="infection" post="in a lethal mouse model: dose-efficacy studies upon oral"/>
 <result pre="fever with thrombocytopenia syndrome disease revealed the risk of SFTSV" exact="infection" post="in Xinjiang, China. Emerg. Microbes Infect.8, 1122–1125. 10.1080/22221751.2019.164557331347462 ZivcecM.SafronetzD.FeldmannH."/>
</results>
